AtriCure, Inc. (NASDAQ:ATRC) Given Consensus Rating of “Moderate Buy” by Brokerages

AtriCure, Inc. (NASDAQ:ATRC) has earned a consensus rating of “Moderate Buy” from the eleven ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $52.2222.

A number of equities analysts have recently weighed in on ATRC shares. BTIG Research set a $54.00 price target on shares of AtriCure in a research note on Wednesday, July 30th. Wall Street Zen raised shares of AtriCure from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AtriCure in a research note on Wednesday, October 8th. Canaccord Genuity Group upped their price target on shares of AtriCure from $53.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research note on Thursday, October 30th.

AtriCure Price Performance

NASDAQ ATRC opened at $32.75 on Wednesday. The stock has a market capitalization of $1.63 billion, a P/E ratio of -53.69 and a beta of 1.59. AtriCure has a 1 year low of $28.29 and a 1 year high of $43.11. The business’s fifty day moving average is $35.85 and its two-hundred day moving average is $33.99. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.83 and a current ratio of 3.94.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Wednesday, October 29th. The medical device company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.10. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.56%. The firm had revenue of $134.27 million during the quarter, compared to analyst estimates of $131.25 million. During the same quarter last year, the business posted ($0.17) EPS. The company’s revenue was up 15.8% on a year-over-year basis. AtriCure has set its FY 2025 guidance at -0.260–0.230 EPS. On average, research analysts forecast that AtriCure will post -0.6 earnings per share for the current fiscal year.

Insider Transactions at AtriCure

In other AtriCure news, Director Sven Wehrwein sold 5,000 shares of the company’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $37.00, for a total transaction of $185,000.00. Following the completion of the sale, the director directly owned 34,374 shares in the company, valued at $1,271,838. This represents a 12.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Justin J. Noznesky sold 3,000 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $36.30, for a total transaction of $108,900.00. Following the completion of the sale, the insider owned 83,964 shares of the company’s stock, valued at approximately $3,047,893.20. The trade was a 3.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 13,000 shares of company stock valued at $473,900 over the last 90 days. Corporate insiders own 3.50% of the company’s stock.

Institutional Trading of AtriCure

Several hedge funds have recently modified their holdings of ATRC. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in AtriCure by 170.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,196,914 shares of the medical device company’s stock worth $70,872,000 after purchasing an additional 1,385,544 shares during the period. Nuveen LLC acquired a new position in AtriCure in the 1st quarter worth $30,666,000. Jennison Associates LLC acquired a new position in AtriCure in the 1st quarter worth $19,139,000. Osterweis Capital Management Inc. acquired a new position in AtriCure in the 1st quarter worth $9,536,000. Finally, Millennium Management LLC boosted its stake in AtriCure by 79.2% in the 1st quarter. Millennium Management LLC now owns 623,323 shares of the medical device company’s stock worth $20,108,000 after purchasing an additional 275,487 shares during the period. Institutional investors and hedge funds own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.